- Datum05.06.2025
- Uhrzeit08:55 - 18:30 Uhr
- Veranstalter
stock3
stock3
Moderator
Cosmo Pharmaceuticals N.V. Aktie
Verkaufen
Kaufen
Cosmo Pharmaceuticals N.V. Chart
Cosmo Pharmaceuticals N.V. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (SIX)
2,89 %
Intraday
1,61 %
1 Woche
19,41 %
1 Monat
-10,68 %
Seit Jahresbeginn
-19,63 %
1 Jahr
9,42 %
3 Jahre
-29,05 %
5 Jahre
-64,44 %
10 Jahre
Passender Service zu Cosmo Pharmaceuticals N.V.
Webinar zu Cosmo Pharmaceuticals N.V.
Kursinformationen (SIX)
- Tagestief / Hoch (Fr)-
- 52W-Tief / Hoch (Fr)41,600-80,600
- Jahrestief / Hoch (Fr)41,600-68,700
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Cosmo Pharmaceuticals N.V.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 04.06.2025 | 2024 | 2,05 € | 3,36 % |
| 10.07.2024 | 2023 | 2,00 € | 2,73 % |
| 31.05.2023 | 2022 | 1,05 € | 2,06 % |
| 01.06.2022 | 2021 | 0,95 € | 1,86 % |
| 29.05.2017 | 2016 | 1,50 € | 0,99 % |
| 31.08.2016 | 2015 | 1,40 € | 0,94 % |
Termine von Cosmo Pharmaceuticals N.V.
- Jul23Cosmo Pharmaceuticals N.V.Q2 2025 Earnings Release
- Mär25Cosmo Pharmaceuticals N.V.Q4 2025 Earnings Release
- Jul29Cosmo Pharmaceuticals N.V.Q2 2026 Earnings Release
Beschreibung
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
